Noninvasive Transcutaneous Glucometer Development

Healthy Clinical Trial

Official title:

Noninvasive Transcutaneous Glucometer Development

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01168076
• Other study ID #: ILS-01-007
• Status: Completed
• Phase: N/A
• First received: July 21, 2010
• Last updated: July 21, 2010
• Start date: December 2001
• Est. completion date: December 2008

Study information

• Verified date: February 2008
• Source: InLight Solutions
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The objective of this study is to assist in the development of a noninvasive device for the accurate measurement of blood glucose levels.

Description:

The feasibility of measuring blood glucose concentration in patients with diabetes mellitus using near infrared (NIR) spectroscopy and multivariate data analysis techniques has been established using general purpose, scientific-grade infrared spectrophotometers under the 90-049 UNM HRRC protocol. Now that the concept of painless, bloodless, and reagent-less clinical laboratory tests has been shown to be viable, the challenge is to bring this technology to the patients who need it. We must develop a device that is portable, affordable, and rugged - all while improving accuracy. We must also improve our understanding of the nature of glucose in whole, intact skin. Since the light beam cannot discriminate plasma glucose in skin blood vessels from glucose in the larger skin interstitial fluid space, the exact nature of the glucose in all tissue compartments contributing to the light-beam signal must be elucidated. The noninvasive measurement can be no more accurate than the reference measurement on which it was based. Finally, we have found that the accuracy of the noninvasive measurement also worsens as a function of time from the initial measurement. This effect is independent of instrumentation drift and is due to physical changes in the patient's skin such as variation of hydration, collagen, vascularity, glycation end-products, etc. To account for these sources of physiologic interference they must be evaluated independently and then compared to errors of the noninvasive predictions over time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: December 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older

• Healthy

• Type I diabetics

• Type II diabetics

• Impaired glucose tolerance

Exclusion Criteria:

• Minor status (<18 years of age)

• Pregnant

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2
• Healthy
• Prediabetic State
• Prediabetic State (IGT)

Locations

Country	Name	City	State
United States	InLight Solutions	Albuquerque	New Mexico

Sponsors (1)

Lead Sponsor	Collaborator
InLight Solutions

Country where clinical trial is conducted

United States,